Terms: = Liver cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Prognosis
23 results:
1. FGF19/fgfr4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract] [Full Text] [Related]
2. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating fgfr4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract] [Full Text] [Related]
3. fgfr4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract] [Full Text] [Related]
4. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating fgfr4 and SRC.
Chen X; Chen J; Feng W; Huang W; Wang G; Sun M; Luo X; Wang Y; Nie Y; Fan D; Wu K; Xia L
Theranostics; 2023; 13(4):1401-1418. PubMed ID: 36923538
[No Abstract] [Full Text] [Related]
5. FGF19/fgfr4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.
Zhou C; Liu Z; Zhou Y; Ren D; Liu K; Qin G; Zhang H; Liang X; Gou S; Wu H
Can J Gastroenterol Hepatol; 2021; 2021():4350417. PubMed ID: 35047460
[TBL] [Abstract] [Full Text] [Related]
7. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract] [Full Text] [Related]
8. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
9. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via fgfr4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
10. EPS364, a Novel Deep-Sea Bacterial Exopolysaccharide, Inhibits liver cancer Cell Growth and Adhesion.
Wang Y; Liu G; Liu R; Wei M; Zhang J; Sun C
Mar Drugs; 2021 Mar; 19(3):. PubMed ID: 33809909
[TBL] [Abstract] [Full Text] [Related]
11. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.
Wang J; Zhao H; Zheng L; Zhou Y; Wu L; Xu Y; Zhang X; Yan G; Sheng H; Xin R; Jiang L; Lei J; Zhang J; Chen Y; Peng J; Chen Q; Yang S; Yu K; Li D; Xie Q; Li Y
Theranostics; 2021; 11(10):5045-5060. PubMed ID: 33754043
[No Abstract] [Full Text] [Related]
12. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not fgfr4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract] [Full Text] [Related]
13. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma.
Seitz T; Freese K; Dietrich P; Thasler WE; Bosserhoff A; Hellerbrand C
Sci Rep; 2020 Mar; 10(1):4546. PubMed ID: 32161315
[TBL] [Abstract] [Full Text] [Related]
14. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
[TBL] [Abstract] [Full Text] [Related]
15. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract] [Full Text] [Related]
16. Fibroblast Growth Factor Receptor 4 (fgfr4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract] [Full Text] [Related]
17. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA
Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259
[TBL] [Abstract] [Full Text] [Related]
18. FGF19/fgfr4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract] [Full Text] [Related]
19. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract] [Full Text] [Related]
20. fgfr4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.
Chen Z; Xie B; Zhu Q; Xia Q; Jiang S; Cao R; Shi L; Qi D; Li X; Cai L
Int J Med Sci; 2013; 10(13):1868-75. PubMed ID: 24324363
[TBL] [Abstract] [Full Text] [Related]
[Next]